Jul 2026· Journal of Immunology· Vol 215· 0 citations
TL;DR
The structure of a broadly reactive anti-human MHC-I mAb, B1.23.2, is determined and a mechanism of anti-MHC-I mAb blocking NK cell inhibitory receptors, which is distinct from other checkpoint mAb mechanisms is proposed.
Abstract
Anti-MHC-I mAbs in human and murine systems can stimulate immune responses to tumors and infections by competitively blocking inhibitory signals delivered by MHC-I-specific inhibitory receptors of several inflammatory cell types (Panda, A.K. et al. J Immunol, 2020). Previous work showed that anti-MHC-I mAbs could activate immune responses by blocking the interactions of HLA with inhibitory receptors like leukocyte immunoglobulin-like receptors LILR (Panda, A.K. et al. Cancer Immunol. Res., 2025).
Here, we determined the structure of a broadly reactive anti-human MHC-I mAb, B1.23.2, in complex with the MHC-I molecule HLA-B*44:05 by both X-ray crystallography and cryo-electron microscopy (cryo-EM) (Jiang J. et al. Commun. Biol. 2025, in review)
The determined structure revealed that B1.23.2 binds to a conserved region on the MHC-I molecule that overlaps with the binding sites for killer immunoglobulin-like receptors (KIRs), indicating the binding competition between anti-MHC-I mAb and KIRs. These studies prompted experiments evaluating B1.23.2 treatment in the human KLM-1 pancreatic cancer model using humanized (NSG-IL15) mice, providing evidence of tumor growth suppression by these anti-MHC-I mAbs.
We proposed a mechanism of anti-MHC-I mAb blocking NK cell inhibitory receptors, which is distinct from other checkpoint mAb mechanisms. These results provide new insights into the structural basis of how anti-MHC-I antibodies can be used in cancer immunotherapy by specifically targeting inhibitory receptor interactions.
This work was supported by the Division of Intramural Research, NIAID, NIH.
Classical and Non-Classical Antigen Presenting Cells (APC)
The biology, disease-associated functions, and therapeutic targeting of nonclassical MHC-I molecules are synthesized, integrating immune checkpoint blockade, antibody-based therapeutics, and MR1- and CD1-restricted cellular immunotherapies into a unified framework.
Monoclonal antibodies (mAbs) directed against MHC class I molecules (MHC-I) have been invaluable for a host of functions including tissue typing for transplantation, exploration of immune activation, and probing molecular structure and dynamics. We previously studied a set of murine mAbs directed against MHC-I to chara...
Jian-Sheng Jiang, K. Natarajan, Reanne R. Towler et al.· bioRxiv· 0 citations
The ML model (DynamiT), trained on simulation-derived structural and dynamical features extracted from 2500 time points, revealed key determinants responsible for T-cell activation with an accuracy of 73.3%.
Jaya Vasavi Pamidimukkala, Roshan Balaji, N. Bhatt et al.· 0 citations
Administration of anti-PD-1 with a bifunctional fusion molecule, anti-TCRβ-IL-2 followed by anti-PD-1 greatly enhanced anti-tumor efficacy leading to tumor cures and long-term protection in several murine models resistant to ICI.
Shantel Angstadt, Lucas A. Horn, Kristen Fousek et al.· Journal of Experimental &...· 0 citations
Interactions between Human Leukocyte Antigen (HLA) molecules and their cognate immunoreceptors are essential for regulating innate and adaptive immune cell functions. Leukocyte Immunoglobulin-like Receptors (LILRs) are key regulators of HLA-mediated immune responses, owing to their broad expression across immune cell p...
Geoff Zhang, Jia Q Truong, Lucy C. Sullivan et al.· bioRxiv· 0 citations
Overall, the established model of MHC-I downregulation (either by bacRNA or synthetic hTLR8 agonists) could be used as a therapeutic strategy to promote anti-tumor responses.
A. Serafino, M. Vermeulen, Yasmín A. Bertinat et al.· PLoS ONE· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.